Journey to Anticoagulant Access Following Payer Rejection of Apixaban.

S Deitelzweig, L Xie, E Terasawa… - American Journal of …, 2023 - search.ebscohost.com
OBJECTIVES: To investigate the journey to oral anticoagulant (OAC) access following
formulary-related rejection of apixaban (Eliquis) and evaluate characteristics associated with …
相关文章

Journey to Anticoagulant Access Following Payer Rejection of Apixaban

S Deitelzweig - The American Journal of Managed Care, 2023 - search.proquest.com
Without treatment, patients with AF face a 5-fold increased risk of stroke, 3 and AF-related
stroke is more likely to be recurrent and fatal than other stroke subtypes. 4, 5 Despite the …

Journey to anticoagulant access following payer rejection of apixaban

S Deitelzweig, L Xie, E Terasawa… - … of managed care, 2023 - pubmed.ncbi.nlm.nih.gov
Objectives To investigate the journey to oral anticoagulant (OAC) access following formulary-
related rejection of apixaban (Eliquis) and evaluate characteristics associated with failure to …